CellAegis Devices Management Team
Rocky Ganske, CEO
Mr. Ganske joined CellAegis in December 2010 as the CEO after having participated on the CellAegis Board of Directors for a year. Mr. Ganske has over 30 years of both public and private company experience in the medical devices, diagnostics and life science fields, and has a broad background in management, operations, science and regulatory; blended with the disciplines of corporate processes, and successful entrepreneurial business ventures. Mr. Ganske has personally led multiple business and IP transactions with both Fortune 100 and Fortune 500 companies.
Prior to CDI, Mr. Ganske served as CEO of Axela, a university diagnostics startup focused on proteomic analysis. Mr. Ganske transitioned Axela to a full operating company, installing Axela’s platform technology in premier institutes in the US, EU and Asia Pacific. Mr. Ganske was instrumental in negotiating and closing significant patent in-licensing transaction with Fortune 100 companies for over 150 patents and applications and oversaw Axela’s acquisition of Xceed Molecular, a genomics diagnostic company.
Mr. Ganske held the position of Chief Operating Officer at Third Wave Technologies (TWTI) in Madison, WI. During his eight year tenure at TWTI, Mr. Ganske was imperative in setting the operational vision and tactical implementation that grew TWTI from a company with great technology to a fully operational company with over $40M of revenue. Third Wave debuted on Nasdaq in February 2001 in an $83 Million IPO, and was bought by Hologic for over $300M.
Prior to Third Wave, Mr. Ganske held various operational, engineering and regulatory management positions over 18 years, including Director of Regulatory Affairs, with Becton Dickinson and Company (BDX).
Vera Belaoussoff, VP of Corporate Development
Ms. Belaoussoff has over 20 years of experience in research and the healthcare industry. She is currently VP, Corporate Development at CellAegis Devices. Prior to joining CellAegis Devices, Ms. Belaoussoff was responsible for pipeline development at YM BioSciences, a development-stage oncology company, where she was responsible for the acquisition of Australian Cytopia Ltd for the JAK inhibitor CYT387, which subsequently resulted in YM BioSciences’ acquisition by US-based Gilead Sciences in 2013.
Ms. Belaoussoff has also provided consulting services to the biotechnology industry, with a focus on strategic development and out-licensing. Ms. Belaoussoff was a healthcare analyst for eight years in the financial services industry, most recently on the buy-side with Scotia Cassels Investment Management where she covered the North American healthcare industry. Prior to that, she was a healthcare analyst in the brokerage industry and participated in over $80 million of biotech financing. Ms. Belaoussoff has her M.Sc. (Molecular Biology) from York University in Toronto, and an Honour’s B.Sc. (Genetics) from the University of Manitoba.
Anne Raghurai, CFO
Ms. Raghurai is a member of the Certified General Accountants Association. During the last 8 years, she established an accounting practice that provides bookkeeping, accounting, financial and income tax services to the small to mid-size market, and specialized accounting services to larger firms. Prior to her full- time practice, Ms. Raghurai was employed with a number of companies in the private and public sectors in various capacities, including, CFO, Controller, Senior Accountant and Accounting Supervisor.
Lahav Gil, Executive Advisor, Design & Engineering
Mr. Gil is a senior Industrial Designer, entrepreneur and innovator with 25 years of experience in product development, commercialization and product management, particularly in the Technology Innovation sector.
Mr.Gil is the CEO and founder of the Kangaroo Group, a Toronto-based technology innovation firm offering product development services to the medical devices and diagnostics industries operating in Canada, US, Europe, Israel and the Far East. As CEO and Director of Design at Kangaroo, Lahav's main responsibilities are Vision, Business Development, Organizational Development, New ventures, New Product Strategy, and Design Leadership and Strategy.
Michaela Shaw, Quality & Regulatory Affairs Manager
Ms. Shaw brings over 10 years experience within the medical device industry where she has focused on leading innovative, start-up medical device firms through the maze of the quality assurance and regulatory requirements to become successful and viable commercial enterprises.
Ms. Shaw has expertise helping companies certify their Quality Management Systems to ISO 13485 and obtain Health Canada, European (CE Mark), Australian and FDA market approvals. Ms. Shaw understands the unique needs of innovative, technology-driven businesses and focuses on developing quality and regulatory strategies that are flexible enough to allow the creative innovations to thrive, while still focusing on the critical medical device regulatory priorities of safety and efficacy.
Denise Aversa, Product Manager
With over 10 years of experience in Marketing, Event Planning and Project Management, Ms. Aversa brings a combination of skill sets to CellAegis, heading up marketing initiatives, trade show and conference planning, as well as being one of the main points of contact on device specific projects. Ms. Aversa’s expertise is coordination. Whether it’s managing a project specific to The autoRIC™ Device, or planning CellAegis’ exhibition at the largest European Cardiology Conference in Europe, her coordination and organization allows the company to move seamlessly between tasks.
Prior to joining CellAegis, Ms. Aversa held management roles with market research firms, as well as various marketing and event planning roles in both the health and beauty, and restaurant industries. Ms. Aversa graduated with a Business Commerce degree from Ryerson University specializing in Marketing Management.